drugset
drugset / Trial / NCT01054352

A Single and Multiple Dose Study to Explore the Safety of JNJ-38224342 in Healthy Patients and Patients With Seasonal Allergies

NCT01054352 ↗

Phase 1 Completed 182 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A single and multiple dose study to assess the safety of JNJ 38224342 compared to placebo in healthy volunteers and in volunteers with seasonal allergies.

Timeline

Start
2010-02
Primary completion
—
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ38224342 Unknown 25 mg Oral
Subject JNJ38224342 Unknown 100 mg Oral
Subject JNJ38224342 Unknown 250 mg Oral
Subject JNJ38224342 Unknown 300 mg Oral
Subject JNJ38224342 Unknown 500 mg Oral
Subject JNJ38224342 Unknown 600 mg Oral
Subject JNJ38224342 Unknown 700 mg Oral
Subject JNJ38224342 Unknown 750 mg Oral
Subject JNJ38224342 Unknown 1250 mg Oral
Subject JNJ38224342 Unknown 2000 mg Oral

Indications

seasonal allergic rhinitis